Researchers identify what drives PARP inhibitor resistance in advanced breast cancer 08 May 2024 Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP inhibitor stops working in women with breast cancer that has spread. This research could ultimately help predict who’s more likely to respond to these drugs, and could lead to more effective ways to treat the disease. Find out more Show/Hide
ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
Existing cancer drugs have potential to benefit thousands more patients 31 Jul 2023 Existing targeted cancer drugs could help even more patients, including some with the most common type of breast cancer, scientists have discovered. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022